Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Metabolon Strengthens Metabolomics Leadership with Acquisition of Lipomics Technologies

Published: Friday, August 03, 2012
Last Updated: Friday, August 03, 2012
Bookmark and Share
Gains proprietary lipids technology platform and further opportunities for diagnostics, personalized medicine and commercial services.

Metabolon, Inc. has announced the completion of its acquisition of Lipomics Technologies, Inc. This transaction combines Metabolon’s world-leading metabolomics technology platform for commercial services and diagnostics with Lipomics’ world-leading TrueMass® Profiling lipids technology platform.

Lipomics’ laboratory facilities will remain at its headquarters in Sacramento, California while Metabolon’s headquarters and laboratories will remain in Research Triangle Park.

Steven M. Watkins, Ph.D., Lipomics’ founder, will join Metabolon’s executive team as chief technology officer. Financial terms of the transaction were not disclosed.

Michael Milburn, Ph.D., chief scientific officer of Metabolon, stated, “Metabolon has pioneered metabolomics technology and is the largest provider of solutions globally to the pharmaceutical, healthcare, consumer products, nutrition and agricultural industries, as well as to hundreds of academic institutions. Lipomics is the leader in technology to analyze lipids, including metabolites of fatty acids, acylcarnitines, sterols, amino acids, bile acids and eicosanoids. Together we have an unprecedented suite of technologies and capabilities to benefit our expanding customer base. The combined technologies will deliver new and improved diagnostic products and personalized medicine solutions for unmet needs, particularly in metabolic disease and cancer.”

“For the past 10 years Lipomics has taken pride in providing the best technology and science for understanding the role of lipids in human disease, principally in metabolic diseases associated with obesity and the lipid remodeling aspects of cancer,” said Dr. Watkins.

Dr. Watkins continued, “The prospect of combining our approach with Metabolon’s global platform is extremely exciting. Integrating the technologies will provide a deep and coherent understanding of biological systems and allow us to produce unparalleled services and products for years to come.”

John Ryals, Ph.D., chief executive officer of Metabolon, expressed his support of the acquisition saying, “By combining Metabolon and Lipomics, we have created the undisputed technology leader in the emerging field of metabolomics. We have product offerings that span from global metabolomics to complex lipid analysis to targeted analysis of many different classes of molecules. By combining our two companies, we have more than 140 employees and 450 clients, have completed 2,000 commercial projects and have 200 scientific papers either published or under review. We are not aware of another company or institution with this record of scientific and commercial achievement in the field of metabolomics.

“We are the leader in the commercialization of metabolomics with a profitable commercial life sciences service business and have launched the world’s first metabolomics-based diagnostic test for type 2 diabetes risk based on biomarkers that measure insulin resistance. We expect that in 2013 we will be marketing additional diagnostic products aimed at diseases related to obesity and cancer, and are committed to maintaining our position as the world’s leader in metabolomics.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Takeda and Metabolon Initiate Research Collaboration
Multiyear research alliance to discover novel targets and biomarkers.
Wednesday, April 18, 2012
Metabolon Secures $13 Million in Series D Financing
New investor Keating Capital, Inc. joins existing investors including Sevin Rosen Funds, Aurora Funds, Harris & Harris Group, Syngenta Ventures, Fletcher Spaght and Fulcrum Financial Partners in the round.
Tuesday, August 30, 2011
USPTO Grants Two New Patents to Metabolon
Metabolon currently holds 17 US Patents related to its biochemical profiling methods, data analysis solutions and biomarkers for disease and toxicity.
Monday, June 20, 2011
Metabolon Receives CLIA Certificate of Registration
Metabolon, Inc. announces the receipt of a Certificate of Registration from the Centers for Medicare and Medicaid Services under the Clinical Laboratory Improvement Amendment (CLIA) for its new facility in Research Triangle Park, NC.
Friday, March 18, 2011
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Diagnostic Thread - Weaving the Future?
Researchers have created diagnostic threads that could pave the way for next-gen implantable and wearable diagnostics.
Unravelling the Roots of Insect’s Waterproof Coating
Researchers have identified the genes that control cuticular lipid production in Drosophila, by performing an RNAi screen and using Direct Analysis in Real Time and GC-MS.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!